The HCP online learning modules are under maintenance due to upgrades with Flash for the 'Develop' and 'Initiate' modules. We appreciate your patience as we resolve this.

Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

ECONOMIC EFFECTIVENESS A STUDY

ECONOMIC EFFECTIVENESS A STUDY

SELF-MONITORING VS. SENSOR AUGMENTED

A study32 was conducted in 2014 to assess the cost-effectiveness of sensor-augmented insulin pump therapy with "Low Glucose Suspend" (LGS) functionality versus standard pump therapy with self-monitoring of blood glucose, in patients with Type 1 diabetes who have impaired awareness of hypoglycaemia.

Summary: After 6 months where a clinical trial-based economic evaluation was performed, the use of sensor-augmented insulin pump therapy with LGS significantly reduced the incidence of severe hypoglycaemia compared to the standard pump therapy. Based on a primary randomised study, the incremental cost-effectiveness ratio (ICER) per severe hypoglycaemic event avoided was $18,257 for all patients and $14,944 for those above 12 years. Over the 6-month period, the cost per quality-adjusted life-year gained was $40,803 for patients aged 12 years and older.

Therefore, sensor-augmented insulin pump therapy with LGS may be considered a cost-effective alternative to standard pump therapy with self-monitoring of blood glucose in hypoglycaemia unaware patients with Type 1 diabetes. View the study here.

 

32. Ly T et al. A Cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value in Health 2014;17:561– 6 9